Accessibility Menu
Sino Biopharmaceutical logo

Sino Biopharmaceutical

(OTC) SBHMY

Current Price$12.55
Market Cap$11.31B
Since IPO (2017)+65%
5 Year-29%
1 Year+36%
1 Month-10%

Sino Biopharmaceutical Financials at a Glance

Market Cap

$11.31B

Revenue (TTM)

CN¥30.57B

Net Income (TTM)

CN¥3.87B

EPS (TTM)

$0.35

P/E Ratio

35.73

Dividend

$0.26

Beta (Volatility)

0.05 (Low)

Price

$12.55

Volume

21

Open

$12.55

Previous Close

$12.55

Daily Range

$12.55 - $12.55

52-Week Range

$11.27 - $20.16

Estimated Earnings Date

Mar 18, 2026

SBHMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Industry

Pharmaceuticals

Employees

21,435

CEO

S Y Tse

Headquarters

Wan Chai, HK

SBHMY Financials

Key Financial Metrics (TTM)

Gross Margin

82.07%

Operating Margin

21.84%

Net Income Margin

7.36%

Return on Equity

7.22%

Return on Capital

14.17%

Return on Assets

3.08%

Earnings Yield

2.80%

Dividend Yield

2.02%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.31B

Shares Outstanding

891.82M

Volume

21

Avg. Volume

23.436

Financials (TTM)

Gross Profit

CN¥24.99B

Operating Income

CN¥6.15B

EBITDA

CN¥6.13B

Operating Cash Flow

CN¥3.16B

Capital Expenditure

-CN¥270.85M

Free Cash Flow

CN¥2.89B

Cash & ST Invst.

CN¥22.96B

Total Debt

CN¥16.07B

Sino Biopharmaceutical Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

CN¥8.79B

+10.7%

Gross Profit

CN¥7.25B

+11.2%

Gross Margin

82.47%

N/A

Market Cap

$11.31B

N/A

Market Cap/Employee

$463.85K

N/A

Employees

24,379

N/A

Net Income

CN¥1.69B

+12.3%

EBITDA

CN¥1.98B

+0.1%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

CN¥22.96B

+57.3%

Total Debt

CN¥16.07B

+64.3%

Accounts Receivable

CN¥7.87B

+58.4%

Inventory

CN¥2.26B

-4.9%

Long Term Debt

CN¥7.65B

+267.8%

Short Term Debt

CN¥8.42B

+9.3%

Return on Assets

3.08%

N/A

Return on Invested Capital

13.69%

N/A

Free Cash Flow

CN¥1.44B

+8.2%

Operating Cash Flow

CN¥1.58B

+2.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNMSFGenmab A/S
$275.00+0.00%
WXXWYWuXi Biologics (Cayman) Inc.
$9.06+0.97%
IVBXFInnovent Biologics, Inc.
$11.06+0.00%
WXIBFWuXi Biologics (Cayman) Inc.
$4.68+17.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.92-0.01%
TAT&T
$20.58+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.15%
CLROClearOne
$6.48+1.01%

Questions About SBHMY

What is the current price of Sino Biopharmaceutical?

Sino Biopharmaceutical is trading at $12.55 per share.

What is the 52-week range for Sino Biopharmaceutical?

Over the past 52 weeks, Sino Biopharmaceutical has traded between $11.27 and $20.16.

How much debt does Sino Biopharmaceutical have?

As of the most recent reporting period, Sino Biopharmaceutical reported total debt of CN¥2.30B.

How much cash does Sino Biopharmaceutical have on hand?

Sino Biopharmaceutical reported CN¥1.06B in cash and cash equivalents in its most recent financial results.

What is Sino Biopharmaceutical’s dividend yield?

Sino Biopharmaceutical currently has a dividend yield of 2.02%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.